58-63-9
58-63-9
Chemical Structure
Inosine
- CAS No.: 58-63-9
- Formula:C10H12N4O5
- Molecular Weight:268.23
IUPAC Name: 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6H-purin-6-one
InChIKey: UGQMRVRMYYASKQ-KQYNXXCUSA-N
SMILES: O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N2C=NC3=C2N=CNC3=O
Biological Activity: Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A1 (A1R) and A2A (A2AR) receptors[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Inosine | 99.94% | Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A1 (A1R) and A2A (A2AR) receptors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Inosine (Standard) | 99.93% | Inosine (Standard) is the analytical standard of Inosine. This product is intended for research and analytical applications. Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A1 (A1R) and A2A (A2AR) receptors. In Vitro:Inosine dose-dependently stimulates cAMP production mediated through the A2AR. Inosine dose-dependently induces hA2AR-mediated ERK1/2 phosphorylation. Inosine (100 μM; 24 hours) reduces oxidative stress in MES 23.5 cells cultured with astrocytes. In Vivo:Inosine (10-100 mg/kg; i.p.) exhibits antinociceptive effect in mice. |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Inosine-15N4 | 98.40% | Inosine-15N4 is the 15N labeled Inosine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Inosine-13C5 | 99.90% | Inosine-13C5 is the 13C5 labeled Inosine (HY-N0092). Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A1 (A1R) and A2A (A2AR) receptors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Inosine-13C3 | Inosine-13C3 is a 13C-labeled Inosine that can be used in pharmacokinetic studies of Inosine. Inosine is an agonist of adenosine receptors A1R and A2AR with anti-inflammatory immunomodulatory, antinociceptive and neuroprotective effects. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Inosine-2,8-d2 | 99.69% | Inosine-2,8-d2 is the deuterium labeled Inosine. Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A1 (A1R) and A2A (A2AR) receptors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Inosine-13C | Inosine-13C is the 13C labeled Inosine. Inosine is an endogenous purine nucleoside produced by catabolism of adenosine. Inosine has anti-inflammatory, antinociceptive, immunomodulatory and neuroprotective effects. Inosine is an agonist for adenosine A1 (A1R) and A2A (A2AR) receptors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Filipe Marques Gonçalves, et al. Signaling pathways underlying the antidepressant-like effect of inosine in mice. Purinergic Signal. 2017 Jun; 13(2): 203-214. [Content Brief]
- [2]. Francisney Pinto Nascimento, et al. Adenosine A1 receptor-dependent antinociception induced by inosine in mice: pharmacological, genetic and biochemical aspects. Mol Neurobiol. 2015;51(3):1368-78. [Content Brief]
- [3]. Ajith A. Welihinda, et al. The adenosine metabolite inosine is a functional agonist of the adenosine A2A receptor with a unique signaling bias. Cell Signal. 2016 Jun; 28(6): 552-560. [Content Brief]
